Loading…
Grifols, S.A. is projected to rise to $9.26 by 2027, a +15% move from its current price of $8.05. GRFS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.91 | $8.05 | $8.20 | +0.05% |
| May 30 | $7.85 | $8.06 | $8.27 | +0.10% |
| May 31 | $7.81 | $8.06 | $8.32 | +0.15% |
| Jun 1 | $7.77 | $8.07 | $8.37 | +0.20% |
| Jun 2 | $7.74 | $8.07 | $8.41 | +0.25% |
| Jun 3 | $7.72 | $8.07 | $8.45 | +0.30% |
| Jun 4 | $7.69 | $8.08 | $8.48 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.69 | $8.08 | $8.48 | +0.35% |
| Week 2 | $7.56 | $8.11 | $8.69 | +0.70% |
| Week 3 | $7.47 | $8.13 | $8.85 | +1.05% |
| Week 4 | $7.40 | $8.16 | $9.00 | +1.40% |
| Week 5 | $7.34 | $8.19 | $9.14 | +1.76% |
| Week 6 | $7.29 | $8.22 | $9.27 | +2.11% |
| Week 7 | $7.25 | $8.25 | $9.39 | +2.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Grifols, S.A. (GRFS) is a healthcare company that engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities.
Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Grifols, S.A. trades at a current price of $7.98 with a market cap of $5.43B and a rank of 1288. The near-term volatility sits at 40%, reflecting a wide trading range and uncertainty.
The forecast provides year-by-year targets showing a bullish long-run path starting in 2027, with 2026 at $7.98 on average and rising toward multi-decade highs by 2050. This creates a view of substantial upside potential, albeit with the inherent uncertainties of equity markets.
A major floor 13.9% below — a decisive break under it would weaken the trend.
The nearest floor, 6.1% below — buyers have tended to step in here.
The nearest ceiling, 8.7% above — a clean break opens room to run.
A major ceiling 20.7% above — clearing it would confirm fresh momentum.
Key GRFS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRFS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.07 | Sell | $8.01 | Buy |
| MA 10 | $7.92 | Buy | $7.99 | Buy |
| MA 20 | $8.00 | Buy | $8.01 | Buy |
| MA 50 | $8.06 | Sell | $8.17 | Sell |
| MA 100 | $8.56 | Sell | $8.42 | Sell |
| MA 200 | $8.99 | Sell | $8.62 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.16 | Neutral |
| Stoch RSI (14) | 81.65 | Sell |
| CCI (20) | 17.29 | Neutral |
| Williams %R (14) | -22.22 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -0.62 | Sell |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 77.78 | Neutral |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 59.43 | Neutral |
| Momentum (10) | 0.49 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 8.09 | Sell |
| ADX (14) | 9.80 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is neutral. RSI14 is 50, with the 50-day simple moving average at $8.05 and the 200-day simple moving average at $9.02. Near-term support sits at $7.56 and resistance at $8.75. The 30-day range spans $7.01 to $9.08, indicating a relatively tight trading band around the current price of $7.98.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.49 | $8.05 | $10.40 | 0% | Neutral | |
| $7.57 | $9.26 | $11.87 | +15% | Neutral | |
| $8.34 | $10.39 | $13.67 | +29% | Bullish | |
| $8.13 | $10.29 | $13.80 | +28% | Bullish | |
| $9.01 | $11.56 | $15.79 | +44% | Bullish | |
| $10.71 | $13.90 | $19.28 | +73% | Bullish | |
| $11.72 | $15.38 | $21.64 | +91% | Bullish | |
| $12.88 | $17.08 | $24.34 | +112% | Bullish | |
| $13.07 | $17.50 | $25.23 | +117% | Bullish | |
| $13.29 | $17.96 | $26.18 | +123% | Bullish | |
| $20.23 | $28.52 | $43.55 | +254% | Bullish | |
| $31.06 | $46.94 | $76.80 | +483% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.49 | $8.05 | $9.42 | +0.00% |
| June 2026 | $7.05 | $8.22 | $9.77 | +2.11% |
| July 2026 | $7.18 | $8.42 | $10.11 | +2.49% |
| August 2026 | $7.07 | $8.34 | $10.08 | -1.05% |
| September 2026 | $7.00 | $8.27 | $10.07 | -0.73% |
| October 2026 | $7.12 | $8.46 | $10.34 | +2.20% |
| November 2026 | $7.16 | $8.52 | $10.47 | +0.75% |
| December 2026 | $7.06 | $8.43 | $10.40 | -1.08% |
Click any year to see its month-by-month GRFS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GRFS to range from $7.49 to $10.40 through 2026. The $8.05 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The GRFS price prediction for 2027 points to an average of $9.26 (low $7.57, high $11.87) — a potential gain of +15% on today's $8.05. Price action looks broadly range-bound.
In 2028, GRFS is projected to trade between $8.34 and $13.67, averaging $10.39 — a potential gain of +29% from today's $8.05. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Grifols, S.A.'s 2029 outlook centres on $10.29, within a $8.13 to $13.80 range. That is -1% versus the projected 2028 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2030, GRFS could reach as high as $15.79, with a base case around $11.56 and support toward $9.01 — roughly +44% from $8.05. Buyers look set to stay in control over this stretch.
Expect GRFS to range from $10.71 to $19.28 through 2031. The $13.90 average target implies a +73% move from current prices. That is up +20% on the projected 2030 average. Momentum favours further upside here.
The GRFS price prediction for 2032 points to an average of $15.38 (low $11.72, high $21.64) — a potential gain of +91% on today's $8.05. Buyers look set to stay in control over this stretch.
In 2033, GRFS is projected to trade between $12.88 and $24.34, averaging $17.08 — a potential gain of +112% from today's $8.05. That is up +11% on the projected 2032 average. Momentum favours further upside here.
Grifols, S.A.'s 2034 outlook centres on $17.50, within a $13.07 to $25.23 range. That is up +2% on the projected 2033 average. That marks a +117% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, GRFS could reach as high as $26.18, with a base case around $17.96 and support toward $13.29 — roughly +123% from $8.05. Momentum favours further upside here.
Expect GRFS to range from $20.23 to $43.55 through 2040. The $28.52 average target implies a +254% move from current prices. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The GRFS price prediction for 2050 points to an average of $46.94 (low $31.06, high $76.80) — a potential gain of +483% on today's $8.05. Momentum favours further upside here.
Investing $1,000 in GRFS today (≈ 124.223602 GRFS) could be worth
$5,830.88
+$4,830.88 (+483%) by 2050 · US Dollar
Based on the average projected GRFS price of $46.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRFSwould be worth at today's price.
$1,000 invested in GRFS on May 27, 2025 (≈ 121.50669 GRFS) would be worth
$978.13
-$21.87 (-2.2%) today · 0.98× · US Dollar
Based on a GRFS entry price of $8.23 vs. today's $8.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.19 | $982.91 | -1.7% |
| 1 month ago | $8.13 | $990.16 | -1.0% |
| 3 months ago | $8.96 | $898.44 | -10.2% |
| 6 months ago | $8.85 | $909.6 | -9.0% |
| 1 year ago | $8.23 | $978.13 | -2.2% |
| All time (5.0y) ago | $17.51 | $459.74 | -54.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRFS forecast.
Our base-case forecast reaches $16.00 around 2033.
Implied market cap at $16.00: $10.89B
The multi-year forecast shows a bullish trajectory starting in 2027, with 2027 avg $9.20 and max $11.84 (min $7.49). By 2030, the average price is projected at $11.40 with a max of $15.67 and a 42.8% ROI. The forecast continues higher into 2040, with an average of $27.64, a max of $42.64, and a 246.3% ROI, and into 2050 with an average of $45.50, a max of $75.39, and a 470.2% ROI.
The path from 2031 through 2035 shows steadily rising averages and higher upside, up to 119.4% ROI in 2035. The forecast is bullish overall, but as with all projections, it carries uncertainty and is not a guarantee. The annualized volatility is 40%, underscoring the potential for meaningful price swings over time.
Tap a question to reveal the answer.
2030 avg $11.40; min $8.84; max $15.67; ROI 42.8%.
The forecast shows a bullish path from 2027 onward, with 2027 avg $9.20 and 2050 avg $45.50, and ROI reaching 470.2% by 2050, though near-term results can be neutral and there are risks.
Yes. The 2040 projection shows avg $27.64 with a 30-day range up to $42.64 and a min around $19.41, yielding a 246.3% ROI.
Current price $7.98; market cap $5.43B; rank 1288.
RSI14 50; SMA50 $8.05; SMA200 $9.02; support $7.56; resistance $8.75; 30-day range $7.01–$9.08.
Grifols, S.A. Community Discussion
0Share your Grifols, S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.